首页> 外文期刊>Kaohsiung Journal of Medical Sciences >Paris saponin VII enhanced the sensitivity of HepG2/ADR cells to ADR via modulation of PI3K/AKT/MAPK signaling pathway
【24h】

Paris saponin VII enhanced the sensitivity of HepG2/ADR cells to ADR via modulation of PI3K/AKT/MAPK signaling pathway

机译:巴黎皂苷VII通过PI3K / AKT / MAPK信号通路的调制增强了HepG2 / ADR细胞对ADR的敏感性

获取原文
       

摘要

To find the effect of Paris saponin VII (PS VII)-mediated PI3K/AKT/MAPK signaling pathway on the sensitivity of ADR-resistant HepG2 cell (HepG2/ADR) cells to ADR. The proliferation inhibitory rates were detected by using MTT assay. Flow cytometry was employed to examine the intracellular accumulation of ADR. The expressions of drug-resistant genes (P-gp, MRP and BCRP) were detected by qRT-PCR, cell apoptosis by Annexin-V-FITC/PI staining, and the expressions of drug-resistance-related proteins, apoptosis-related proteins, and PI3K/AKT/MAPK pathway-related proteins were determined by Western blotting. HepG2/ADR and HepG2 cells treated with PS VII (0.88, 1.32, 1.98, and 2.97 μM) for 48 hours showed increased proliferation inhibitory rate in a dose-dependent manner. HepG2/ADR cells treated PS VII (0.88, 1.32, 1.98 μM) for 48 hours showed decreased IC50 of ADR. Compared with HepG2/ADR cells treated with ADR (5 nM), those treated with PS VII (≤1.98 μM) and ADR (5 nM) showed enhanced ADR accumulation, decreased drug-resistant gene expressions, increased cell apoptosis with unregulated Bax and cleaved caspase-3 and downregulated Bcl-2, as well as the inhibition of PI3K/AKT/MAPK pathway. Moreover, the combination of ADR (5 nM), PS VII (1.98 μM), and LY294002 (PI3K/AKT inhibitor, 20 μM)/SB203580 (P38 inhibitor, 20 μM) for 48 hours could further decreased the HepG2/ADR cell viability, but induced cell apoptosis, accompanying with the decreased expressions of drug-resistant genes. PS VII could downregulate the expressions of drug-resistance genes, increase intracellular accumulation of ADR, promote cell apoptosis, and enhance the sensitivity of HepG2/ADR cells to ADR via PI3K/AKT/MAPK.
机译:寻找巴黎皂苷VII(PS VII)介导的PI3K / AKT / MAPK信号通路对ADR抗性HepG2细胞(HepG2 / ADR)细胞对ADR的敏感性的影响。通过使用MTT测定检测增殖抑制率。使用流式细胞术检查ADR的细胞内积累。通过QRT-PCR,细胞凋亡,通过膜蛋白-V-FITC / PI染色,以及药物抵抗相关蛋白,凋亡相关蛋白质的表达检测耐药基因(P-GP,MRP和BCRP)的表达,凋亡相关蛋白质并且通过蛋白质印迹测定PI3K / AKT / MAPK途径相关的蛋白质。用PS VII(0.88,1.32,1.98和2.97μm)处理的Hepg2 / Adr和Hepg2细胞48小时显示出增加的增殖抑制率以剂量依赖性方式。 HepG2 / ADR细胞处理的PS VII(0.88,1.32,1.98μm)48小时显示ADR的IC50降低。与ADR(5nm)处理的HepG2 / ADR细胞相比,用PS VII(≤1.98μm)和ADR(5nm)处理的那些表现出增强的ADR积累,降低耐药基因表达,增加细胞凋亡,具有未调节的吠叫和切割Caspase-3和下调的BCL-2,以及PI3K / AKT / MAPK途径的抑制作用。此外,ADR(5nM),PS VII(1.98μm)和LY294002(PI3K / AKT抑制剂,20μM)/ SB203580(P38抑制剂,20μm)的组合可以进一步降低HepG2 / ADR细胞活力但是诱导细胞凋亡,随着耐药基因的降低而伴随。 PS VII可以下调耐药基因的表达,增加ADR的细胞内积累,促进细胞凋亡,并通过PI3K / AKT / MAPK增强HepG2 / Adr细胞对ADR的敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号